Wewer Albrechtsen, et al (2015)
Indications & Research Applications Published research has examined Retatrutide in the context of obesity and type 2 diabetes, with studies reporting effects on body weight, glycemic measures, and metabolic biomarkers [3]
Clinical practices and adoption rates among providers Patient compliance and adherence Mixed sentiments abound in both the healthcare and insurance industries about actual take-up rates, with some bullish about the outlook given the hype generated both in the clinical setting and commercially
Regulatory Status: Retatrutide is an investigational compound in phase 3 clinical trials (as of June 29, 2025) and is not approved by the FDA or any other regulatory body for clinical use
This is metabolic adaptation, and it is not a sign that your medication has stopped working
MeAgain keeps custom symptoms, cycle notes, heat notes, meals, water, the weekly shot, and the weight trend in one timeline so a rough stretch becomes a pattern you can inspect instead of a feeling you have to describe from memory